drugset / Trial / NCT02887534

Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain

NCT02887534

RandomizedParallel-groupDouble-blindTreatment

Summary

A phase 2 randomized clinical trial to evaluate efficacy and safety of SPARC1401 at three dose levels in patients with acute low back pain

Timeline

Start
2016-11
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SPARC1401 Unknown
Comparator Tizanidine Small molecule

Indications

No indication recorded.